Rendering shown — your prescription arrives in Parke's unmarked, cold-chain packaging. Compounded medications are not FDA-approved.
Tirzepatide RX
A once-weekly injection that works on two hormone pathways at once — built into a plan by the clinician who reviews your intake, and adjusted for as long as you're in care.
- Dual GLP-1 + GIP receptor action, one weekly dose
- Titrated by your clinician, reviewed before every refill
- Free cold-chain delivery, unmarked packaging
- Unlimited clinician messaging between refills
Multi-month plans show the average monthly cost and are billed upfront. Your final plan and price are set with your clinician — and you can pause or cancel anytime.
Two hormones.
One considered protocol.
Most weight-loss medication works on a single pathway. Tirzepatide speaks to two.
Quiets the noise
Slows gastric emptying and works on appetite signaling — meals feel satisfying sooner, and the constant background chatter about food fades.
Works with your metabolism
The second pathway — involved in how your body responds to insulin and handles energy after meals — is what sets tirzepatide apart from GLP-1-only treatment.
Together, they do what neither does alone — and your clinician decides if that's right for you.
Thirty seconds, once a week.
Tirzepatide is designed to disappear into your actual life — not reorganize it.
- One small injection, weekly. Same day each week, about 30 seconds, with guided instructions in your member portal.
- No clinics, no pharmacy lines. Everything ships cold-chain to your door in unmarked packaging.
- A clinician on your side of it. Questions between refills are answered by your care team, usually the same business day.
Built for real life
Titrated to you — never rushed.
Your dose is a clinical decision that evolves as your body responds. This is the typical arc, though yours may differ.
Your body acclimates
Treatment begins at the lowest dose while your clinician watches how you respond — most early side effects, if any, show up and settle here.
The working dose
If your first month goes well, your clinician steps you up. Many members feel the effect on appetite become unmistakable in this range.
Only as far as necessary
Higher doses exist — but they're used only when your progress and your clinician say so. The lowest dose that works is the right dose.
Every step is reviewed. Dose changes at Parke are made by the clinician who knows your chart — never by an auto-renewal system. Adjustments, including slowing down or pausing, are included in your plan. New to the word? Titration, explained, in the Journal.
Studied more than any weight medication of its generation.
Average body-weight reduction at the highest studied dose over 72 weeks — in clinical trials of branded, FDA-approved tirzepatide.
In large clinical trials, participants taking branded tirzepatide alongside diet and exercise lost substantially more weight on average than those on GLP-1–only medication — which is why many clinicians consider the dual-action approach when GLP-1 alone hasn't been enough.
Those results come from trials of FDA-approved branded tirzepatide products, not compounded preparations, which are not FDA-approved or evaluated. Compounded tirzepatide is not interchangeable with any branded product. Individual results vary with dose, adherence, lifestyle, and history — and are never guaranteed.
Two good options. One right answer — yours.
You don't have to choose alone. Your clinician recommends one based on your history, goals, and how you respond — and can adjust course later.
On tirzepatide, in their words.
“Semaglutide got me partway. My clinician suggested the switch, walked me through why, and stayed on it with me week by week.”
“The Sunday-night injection takes less time than making coffee. The food noise going quiet was the part nobody prepared me for.”
“They started me low and never rushed the dose. When week two felt rough, a real doctor answered that afternoon — not a chatbot.”
Individual results and experiences vary. Testimonials reflect the experiences of specific members and are not a guarantee of outcomes. Treatment is prescribed only when a licensed clinician determines it is appropriate.
Side effects, said plainly.
You deserve the whole picture before you start — not after.
Common, usually temporary
- Nausea, especially in the first weeks and after dose increases
- Constipation or diarrhea
- Reduced appetite (that's the mechanism, but it can be abrupt)
- Fatigue or mild injection-site reactions
Rare, but serious — call your clinician
- Severe abdominal pain that doesn't pass (possible pancreatitis)
- Gallbladder symptoms — pain, fever, yellowing skin
- Signs of low blood sugar if you take insulin or sulfonylureas
- Allergic reactions — swelling, trouble breathing
How Parke handles this: your clinician screens your full history before prescribing, starts you at the lowest dose, and is reachable between refills — most side-effect questions are answered the same business day, and dose adjustments are included in every plan. Full details in the important safety information.
Asked, answered, plainly.
Can't find your question? Message us — a human on our care team replies, usually within a few hours.
Tirzepatide is a once-weekly injectable medication that activates two hormone receptors — GLP-1 and GIP — involved in appetite, digestion, and how your body handles energy. At Parke it's prescribed as a compounded preparation by a licensed clinician, when appropriate, and prepared by state-licensed US pharmacies.
Semaglutide works on one pathway (GLP-1); tirzepatide works on two (GLP-1 and GIP). In head-to-head trials of the branded, FDA-approved products, tirzepatide produced greater average weight reduction. That doesn't make it right for everyone — your clinician weighs your history, goals, and tolerance when recommending one.
Often, yes — it's one of the most common conversations our clinicians have. If your progress on GLP-1 alone has stalled, your clinician can evaluate a switch, set an appropriate starting dose, and manage the transition inside your existing plan.
Eligibility is a clinical decision made from your full intake. Tirzepatide is not prescribed during pregnancy or breastfeeding, or with a personal or family history of medullary thyroid carcinoma or MEN 2, among other factors your clinician reviews before any prescription is written.
Everything: your medication, clinician reviews, dose adjustments, unlimited care-team messaging, and free cold-chain shipping. No membership fees, no hidden charges, no cancellation fees.
Message your care team — clinical questions are usually answered the same business day. Your clinician can slow your titration, hold a dose, or recommend supportive care. Most early side effects settle as your body adjusts.
Anytime, from your member portal, in about two clicks. No contracts, no cancellation fees, no retention phone calls. Multi-month plans can be paused with your remaining shipments held.
Explore other concierge treatments.
The stronger option, considered properly starts with a conversation.
A private 2-minute assessment, read by a clinician who will decide with you — tirzepatide, semaglutide, or neither.
No charge unless a clinician approves your plan · Pause or cancel anytime
Important safety information — compounded tirzepatide
Warning: Tirzepatide-containing medicines caused thyroid C-cell tumors in rodent studies; it is unknown whether they cause such tumors in humans. Do not use with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or during pregnancy or breastfeeding. Common side effects include nausea, vomiting, diarrhea, constipation, decreased appetite, and abdominal pain. Serious risks include pancreatitis, gallbladder disease, kidney injury, severe gastrointestinal disease, and low blood sugar when combined with insulin or sulfonylureas. Tell your clinician about all medical conditions — including a history of gastroparesis, diabetic retinopathy, or kidney or pancreas problems — and all medications before starting treatment. Stop use and seek immediate care for severe abdominal pain, symptoms of an allergic reaction, or vision changes.
Compounded tirzepatide is prepared by state-licensed US compounding pharmacies and is not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. It is not the same as, interchangeable with, or a substitute for any FDA-approved branded tirzepatide product. Parke is not affiliated with, endorsed by, or sponsored by the manufacturers of branded tirzepatide products; all trademarks belong to their respective owners. Clinical-trial results referenced on this page come from studies of FDA-approved branded products and do not apply to compounded formulations. This page is informational, is not medical advice, and does not guarantee any outcome. If you are experiencing a medical emergency, call 911.